Discovery of Herbacetin as a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy (Adv. Sci. 2/2022) | Zendy

Zhang Shujing | Zendy; Wang Yingchao | Zendy; Yu Min | Zendy; Shang Ye | Zendy; Chang Yanxu | Zendy; Zhao Hong | Zendy; Kang Yu | Zendy; Zhao Lu | Zendy; Xu Lei | Zendy; Zhao Xiaoping | Zendy; Difrancesco Dario | Zendy; Baruscotti Mirko | Zendy; Wang Yi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discovery of Herbacetin as a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy (Adv. Sci. 2/2022)

Author(s) -

Zhang Shujing,

Wang Yingchao,

Yu Min,

Shang Ye,

Chang Yanxu,

Zhao Hong,

Kang Yu,

Zhao Lu,

Xu Lei,

Zhao Xiaoping,

Difrancesco Dario,

Baruscotti Mirko,

Wang Yi

Publication year - 2022

Publication title -

advanced science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.388

H-Index - 100

ISSN - 2198-3844

DOI - 10.1002/advs.202270009

Subject(s) - sgk1 , medicine , muscle hypertrophy , cardiology , glucocorticoid

Herbacetin In article number 2101485, Xiaoping Zhao, Yi Wang, and co‐workers describe that herbacetin (HBT) derived from traditional Chinese medicine Rhodiola rosea (known as “golden root” in Europe) is identified as a novel SGK1 inhibitor to significantly alleviate myocardial hypertrophy, which brings dawn to patients with heart failure as well as other SGK1‐driven diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research